Cros

Putting Patients First: How to Set Up Clinical Trial Patients for Success, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, January 12, 2023
Associate, Trust, Pragmatism, Heart, Cros, Centricity, Patient, Clinical trial, Human, Pharmaceutical industry

TORONTO, Jan. 12, 2023 /PRNewswire-PRWeb/ -- Patients (and their families) are at the heart of clinical research — without them there is no trial. Therefore, putting patients first should be critical within a clinical trial process. Yet 85 percent of all clinical trials fail to recruit enough patients and dropout rates are at all-time highs. Currently 80 percent of trials are delayed due to these challenges.

Key Points: 
  • The speakers will share practical ways to build trust and demonstrate to patients that their time and contribution is valued.
  • TORONTO, Jan. 12, 2023 /PRNewswire-PRWeb/ -- Patients (and their families) are at the heart of clinical research — without them there is no trial.
  • Therefore, putting patients first should be critical within a clinical trial process.
  • Yet 85 percent of all clinical trials fail to recruit enough patients and dropout rates are at all-time highs.

Novotech Acquires European CRO, Strengthens Global Operations

Retrieved on: 
Thursday, January 12, 2023
Gene, Cros, Culture, Friends, Frost, Acquisition, Cell, Fine chemical, European

Novotech CEO Dr. John Moller said: "This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs.

Key Points: 
  • Novotech CEO Dr. John Moller said: "This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs.
  • EastHORN and Novotech have been working together for many years and we share a culture of clinical excellence in biotech drug development.
  • EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team.
  • In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

Retrieved on: 
Thursday, January 12, 2023
IND, Gene, CBR, Cros, Biotechnology, IDE, FDA, US FDA, Drug development, NDA, BLA, Bureau of Oceans and International Environmental and Scientific Affairs, Frost, Acquisition, CGMP, Toxicology, Cell, Fine chemical, Medical device, Pharmaceutical industry

CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.

Key Points: 
  • CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.
  • Novotech CEO Dr. John Moller said: "CBR will provide decades of FDA regulatory experience for our biotech clients.
  • Navigating novel product development and achieving multiple approvals has built our expertise to support the complex development needs of clients worldwide which will now support Novotech clients.
  • We look forward to working with Novotech clients to support their drug development programs in the US and globally.

Novotech Acquires European CRO – Strengthens Global Operations

Retrieved on: 
Thursday, January 12, 2023
Gene, Cros, Culture, Friends, Frost, Acquisition, Cell, Fine chemical, European

SINGAPORE, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.

Key Points: 
  • SINGAPORE, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • “This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs.
  • EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team.
  • In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

Novotech Acquires US-based Drug Development Consulting Firm, CBR International - Expands Drug Development and FDA Regulatory Expertise

Retrieved on: 
Monday, January 9, 2023
IND, Gene, CBR, Cros, Biotechnology, IDE, FDA, US FDA, Drug development, NDA, BLA, Bureau of Oceans and International Environmental and Scientific Affairs, Frost, Acquisition, CGMP, Toxicology, Cell, Fine chemical, Pharmaceutical industry, Medical device

CBR was founded in 2002 as a consultancy company focused on assisting biotechnology and pharma companies navigate FDA requirements from early-stage development through to approval.

Key Points: 
  • CBR was founded in 2002 as a consultancy company focused on assisting biotechnology and pharma companies navigate FDA requirements from early-stage development through to approval.
  • CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.
  • CBR’s specific regulatory expertise and services include long-range Regulatory Strategy and Writing, FDA Representation, eSubmissions, and Scientific Affairs to support requirements for cGMP commercial product development.
  • This acquisition, together with Novotech’s existing regulatory affairs capability, creates a large global group of experts in toxicology, drug development, and global regulatory submissions support.

Novotech Acquires European CRO – Strengthens Global Operations

Retrieved on: 
Monday, January 9, 2023
Gene, Cros, Culture, Friends, Frost, Acquisition, Cell, Fine chemical, European

SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.

Key Points: 
  • SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • “This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs.
  • EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team.
  • In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

Novotech is Gold Sponsor at Biotech Showcase 2023

Retrieved on: 
Tuesday, December 20, 2022
US FDA, KOL, Drug development, Research, Best practice, Gene, AU, NDA, Cros, Growth, GlobalData, Frost, Data management, Cell, Biotechnology, Pharmaceutical industry, IND

SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.

Key Points: 
  • SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.
  • Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.
  • Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.
  • The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific.

Novotech is Gold Sponsor at Biotech Showcase 2023

Retrieved on: 
Tuesday, December 20, 2022
US FDA, KOL, Drug development, Research, Best practice, Gene, NDA, SAN, Cros, Growth, GlobalData, Frost, Data management, Cell, Biotechnology, Pharmaceutical industry, Online shopping, Risk management, IND

SAN FRANCISCO, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Novotech, the Asia Pacific centered biotech specialist CRO, is proud to be Gold Sponsor at Biotech Showcase 2023.

Key Points: 
  • SAN FRANCISCO, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Novotech, the Asia Pacific centered biotech specialist CRO, is proud to be Gold Sponsor at Biotech Showcase 2023.
  • Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.
  • Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.
  • The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific.

Datacubed Health, a Sterling Partners Portfolio Company, Achieves Impressive 150% YOY Growth

Retrieved on: 
Tuesday, December 20, 2022
Clinical trial, Translation, Rigidity, Televisit, COVID-19, Sterling, Health, EPRO, Cros, Patient engagement in Canada, Growth, Clinical data management, Entrepreneurship, Investment, Guest appearance, Datacube Inc., Medicine, Fine chemical, Pharmaceutical industry

Brooklyn, New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Datacubed Health (“Datacubed”), a digital health technology company that supports hybrid and decentralized clinical trials, and Sterling Partners (“Sterling”), a prominent investment management firm, announced December 20, 2022, substantial year-over-year growth.

Key Points: 
  • Brooklyn, New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Datacubed Health (“Datacubed”), a digital health technology company that supports hybrid and decentralized clinical trials, and Sterling Partners (“Sterling”), a prominent investment management firm, announced December 20, 2022, substantial year-over-year growth.
  • Following its initial investment in 2020, Sterling has continued to support Datacubed.
  • At its founding, Datacubed was rooted in behavioral science and offered a gamified ePRO solution designed to boost patient engagement.
  • Steven Taslitz, Co-Founder and Chairman of Sterling Partners, said, “We believe the industry is at an inflection point.

FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site

Retrieved on: 
Monday, December 19, 2022
Partnership, Research, SomaLogic, Cros, Epitope, CVS, Plasma, Beth Israel Deaconess Medical Center, Washington University in St. Louis, Management, Fine chemical

TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan.

Key Points: 
  • TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan.
  • The new site will offer the 7,000-plex SomaScan® Assay in their labs and provide SomaScan data to their customers.
  • By becoming a SomaLogic Certified Site, FonesLife can now run assays on SomaLogic’s SomaScan Platform—the largest commercially available proteomic platform—and accelerate their own research and provide additional opportunities to utilize the industry-leading platform in the Asia-Pacific region.
  • SomaLogic’s proprietary SomaScan Platform was designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications.